Could a few drops replace the bottle? new cataract study tests simpler recovery
NCT ID NCT07276802
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways to manage pain and swelling after cataract surgery. One uses a single injection and two types of eye drops, the other uses three different drops multiple times a day. 40 adults having surgery on both eyes will try each method and say which they prefer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A male or female subject in good general health, \> 22 years of age at the time of the screening visit * A subject must be able to comprehend and willing to give informed consent * A woman of child-bearing potential must not be pregnant or lactating. * A subject has the availability, willingness and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits * A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned * A subject with clear ocular media other than cataract in their scheduled operative eye * A subject with normal OCT of the macula in both eyes * A subject has the potential for a post-operative Snellen BCDVA of 20/30 or better in both eyes Exclusion Criteria: * A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye * A subject with any moderate to severe lid, conjunctival or corneal findings in either eye at the screening visit * A subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit * A subject with a known sensitivity to any of the study medications. * A subject with a history as a steroid responder or glaucoma * A subject with a known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article * A subject with only one eye with potentially good vision * A subject with a known pathology that may affect visual acuity (as determined by the Investigator); particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) in their scheduled surgical eye * A subject that has a condition associated with the fluctuation of hormones that could lead to refractive changes * A subject with amblyopia or strabismus * A subject has a history of ocular trauma in their scheduled surgical eye * A subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening * A subject with pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) in their scheduled surgical eye. * A subject with a clinically significant corneal abnormality (e.g., stromal, epithelial or endothelial dystrophies) that, in the best judgment of the investigator, is likely to interfere with the outcomes of the study * A subject with an inability to achieve keratometric stability for contact lens wearers * A subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye * A subject with uncontrolled glaucoma * A subject that requires the use of systemic or ocular medications that may affect vision, ocular inflammation or pain * A subject with an acute or chronic disease, or illness, that would increase risk or confound study results (e.g., autoimmune disease, connective tissue disease, immunocompromised, suspected glaucoma, glaucomatous changes in the fundus or visual field, other source of ocular inflammation, etc.) * A subject with an uncontrolled systemic disease: A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study * A subject with diabetes that is poorly controlled * A subject currently participating or has participated in another clinical trial within 30 days prior to enrollment. Intra-Operative Exclusion Criteria (Surgical Complications): * Sulcus-sulcus or bag-sulcus fixation * Posterior capsular rupture or zonular dialysis * Disruption of anterior hyaloid face * Vitreous loss * Floppy iris syndrome * Inability to place IOL in capsular bag * Significant anterior chamber hyphema * Significant zonular rupture.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cataract are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Harvard Eye Associates
Laguna Hills, California, 92653, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lens that could let cataract patients see near and far without glasses
- One operation for cataract and glaucoma? eye surgeons test a Two-in-One approach
- Eye drops may shield the cornea after cataract surgery
- A simple blood draw might reveal hidden eye lymphoma
- Can a new lens make glasses obsolete after cataract surgery?
- Can a new lens design sharpen vision after macular surgery?